98 related articles for article (PubMed ID: 9219487)
1. Serotonin reuptake inhibitor discontinuation syndrome: a hypothetical definition. Discontinuation Consensus panel.
Schatzberg AF; Haddad P; Kaplan EM; Lejoyeux M; Rosenbaum JF; Young AH; Zajecka J
J Clin Psychiatry; 1997; 58 Suppl 7():5-10. PubMed ID: 9219487
[TBL] [Abstract][Full Text] [Related]
2. SSRI withdrawal syndrome in children and adolescents: a narrative literature review.
Khan YS; Khoodoruth MAS; Albobali Y; Haddad PM
Expert Opin Drug Saf; 2023; 22(5):381-390. PubMed ID: 37339264
[TBL] [Abstract][Full Text] [Related]
3. An Oppositional Tolerance Account for Potential Cognitive Deficits Caused by the Discontinuation of Antidepressant Drugs.
Colzato L; Zhang W; Walter H; Beste C; Stock AK
Pharmacopsychiatry; 2021 Nov; 54(6):252-260. PubMed ID: 34293810
[TBL] [Abstract][Full Text] [Related]
4. Discontinuing antidepressants: Pearls and pitfalls.
Zwiebel SJ; Viguera AC
Cleve Clin J Med; 2022 Jan; 89(1):18-26. PubMed ID: 34983798
[TBL] [Abstract][Full Text] [Related]
5. Steps Following Attainment of Remission: Discontinuation of Antidepressant Therapy.
Shelton RC
Prim Care Companion J Clin Psychiatry; 2001 Aug; 3(4):168-174. PubMed ID: 15014601
[TBL] [Abstract][Full Text] [Related]
6. Current strategies for tapering psychiatric drugs: Differing recommendations, impractical doses, and other barriers.
Eserian JK; Blanco VP; Mercuri LP; Matos JDR; Galduróz JCF
Psychiatry Res; 2023 Nov; 329():115537. PubMed ID: 37837810
[TBL] [Abstract][Full Text] [Related]
7. Antidepressant Discontinuation Syndrome: A Common but Underappreciated Clinical Problem.
Rizkalla M; Kowalkowski B; Prozialeck WC
J Am Osteopath Assoc; 2020 Feb; ():. PubMed ID: 32077900
[No Abstract] [Full Text] [Related]
8. Clinical management of antidepressant discontinuation.
Rosenbaum JF; Zajecka J
J Clin Psychiatry; 1997; 58 Suppl 7():37-40. PubMed ID: 9219493
[TBL] [Abstract][Full Text] [Related]
9. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial.
Rosenbaum JF; Fava M; Hoog SL; Ascroft RC; Krebs WB
Biol Psychiatry; 1998 Jul; 44(2):77-87. PubMed ID: 9646889
[TBL] [Abstract][Full Text] [Related]
10. Antidepressant discontinuation: a review of the literature.
Lejoyeux M; Adès J
J Clin Psychiatry; 1997; 58 Suppl 7():11-5; discussion 16. PubMed ID: 9219488
[TBL] [Abstract][Full Text] [Related]
11. Newer antidepressants and the discontinuation syndrome.
Haddad P
J Clin Psychiatry; 1997; 58 Suppl 7():17-21; discussion 22. PubMed ID: 9219489
[TBL] [Abstract][Full Text] [Related]
12. FINISH: remembering the discontinuation syndrome. Flu-like symptoms, Insomnia, Nausea, Imbalance, Sensory disturbances, and Hyperarousal (anxiety/agitation).
Berber MJ
J Clin Psychiatry; 1998 May; 59(5):255. PubMed ID: 9632038
[No Abstract] [Full Text] [Related]
13. Discontinuation symptoms after treatment with serotonin reuptake inhibitors: a literature review.
Zajecka J; Tracy KA; Mitchell S
J Clin Psychiatry; 1997 Jul; 58(7):291-7. PubMed ID: 9269249
[TBL] [Abstract][Full Text] [Related]
14. Adverse Effects of Antidepressant Medications and their Management in Children and Adolescents.
Strawn JR; Mills JA; Poweleit EA; Ramsey LB; Croarkin PE
Pharmacotherapy; 2023 Jul; 43(7):675-690. PubMed ID: 36651686
[TBL] [Abstract][Full Text] [Related]
15. Estimating Risk of Antidepressant Withdrawal from a Review of Published Data.
Horowitz MA; Framer A; Hengartner MP; Sørensen A; Taylor D
CNS Drugs; 2023 Feb; 37(2):143-157. PubMed ID: 36513909
[TBL] [Abstract][Full Text] [Related]
16. A Focus on Abuse/Misuse and Withdrawal Issues with Selective Serotonin Reuptake Inhibitors (SSRIs): Analysis of Both the European EMA and the US FAERS Pharmacovigilance Databases.
Chiappini S; Vickers-Smith R; Guirguis A; Corkery JM; Martinotti G; Schifano F
Pharmaceuticals (Basel); 2022 May; 15(5):. PubMed ID: 35631391
[TBL] [Abstract][Full Text] [Related]
17. Protracted withdrawal syndrome after stopping antidepressants: a descriptive quantitative analysis of consumer narratives from a large internet forum.
Hengartner MP; Schulthess L; Sorensen A; Framer A
Ther Adv Psychopharmacol; 2020; 10():2045125320980573. PubMed ID: 33489088
[TBL] [Abstract][Full Text] [Related]
18. Dependence, withdrawal and rebound of CNS drugs: an update and regulatory considerations for new drugs development.
Lerner A; Klein M
Brain Commun; 2019; 1(1):fcz025. PubMed ID: 32954266
[TBL] [Abstract][Full Text] [Related]
19. Development of Obsessive-Compulsive Symptoms Following Abrupt Discontinuation of Venlafaxine.
Gahr M; Hiemke C; Kölle MA
Front Psychiatry; 2020; 11():32. PubMed ID: 32116847
[TBL] [Abstract][Full Text] [Related]
20. Focus on Clozapine Withdrawal- and Misuse-Related Cases as Reported to the European Medicines Agency (EMA) Pharmacovigilance Database.
Chiappini S; Schifano F; Corkery JM; Guirguis A
Brain Sci; 2020 Feb; 10(2):. PubMed ID: 32079135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
